| Date | Panel | Item | Activity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mendeliome v1.4534 | RPA2 |
Zornitza Stark gene: RPA2 was added gene: RPA2 was added to Mendeliome. Sources: Literature Mode of inheritance for gene: RPA2 was set to BOTH monoallelic and biallelic, autosomal or pseudoautosomal Publications for gene: RPA2 were set to 41703052; 39231615 Phenotypes for gene: RPA2 were set to Telomere syndrome, MONDO:0100137, RPA2-related Review for gene: RPA2 was set to RED Added comment: PMID 41703052 reports a 6‑year‑old individual from a consanguineous family who is homozygous for the splice‑site variant c.409‑2A>G (p.Q136_K138del). The patient presented with early‑onset bone‑marrow failure, immunodeficiency, microcephaly, dysmorphic features and severely short telomeres. The heterozygous parents are asymptomatic carriers. Functional studies showed ~50% reduction of RPA2 protein, destabilization of the OB‑fold ssDNA‑binding groove, impaired telomere binding, severe telomere shortening, increased telomere variant repeats and chromosome end‑to‑end fusions, supporting a loss‑of‑function mechanism. PMID 39231615 reports 2 individuals from 2 unrelated families with a heterozygous missense variant c.767A>G (p.Y256C) presenting with adult‑onset telomere biology disorder characterized by pleuroparenchymal fibroelastosis/interstitial lung disease, short telomeres, bone‑marrow failure (macrocytic anemia, myelodysplastic syndrome), liver disease and osteoporosis. Variant is ultra‑rare (gnomAD v4 1 het) and predicted deleterious. Functional studies (RPE1 knock‑in cell lines, RFWD3 interaction and ubiquitination assays, ATR signaling, telomere length assays, and a mouse model lethal in homozygous state) demonstrate loss‑of‑function effects, supporting pathogenicity. Both patients acquired, in a subset of blood cells, somatic genetic rescue events in either POT1 genes or TERT promoters known to counteract the accelerated telomere shortening. Sources: Literature |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mendeliome v1.2220 | RFWD3 | Bryony Thompson Publications for gene: RFWD3 were set to 28691929 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mendeliome v1.2219 | RFWD3 | Bryony Thompson Classified gene: RFWD3 as Amber List (moderate evidence) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mendeliome v1.2219 | RFWD3 | Bryony Thompson Gene: rfwd3 has been classified as Amber List (Moderate Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mendeliome v1.2218 | RFWD3 | Bryony Thompson reviewed gene: RFWD3: Rating: AMBER; Mode of pathogenicity: None; Publications: 28691929, 38058754; Phenotypes: Fanconi anemia MONDO:0019391; Mode of inheritance: BIALLELIC, autosomal or pseudoautosomal | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mendeliome v0.2009 | RFWD3 | Zornitza Stark Marked gene: RFWD3 as ready | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mendeliome v0.2009 | RFWD3 | Zornitza Stark Gene: rfwd3 has been classified as Red List (Low Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mendeliome v0.2009 | RFWD3 | Zornitza Stark Phenotypes for gene: RFWD3 were changed from to Fanconi anemia, complementation group W, MIM# 617784 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mendeliome v0.2008 | RFWD3 | Zornitza Stark Publications for gene: RFWD3 were set to | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mendeliome v0.2007 | RFWD3 | Zornitza Stark Mode of inheritance for gene: RFWD3 was changed from Unknown to BIALLELIC, autosomal or pseudoautosomal | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mendeliome v0.2006 | RFWD3 | Zornitza Stark Classified gene: RFWD3 as Red List (low evidence) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mendeliome v0.2006 | RFWD3 | Zornitza Stark Gene: rfwd3 has been classified as Red List (Low Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mendeliome v0.2005 | RFWD3 | Zornitza Stark reviewed gene: RFWD3: Rating: RED; Mode of pathogenicity: None; Publications: 28691929; Phenotypes: Fanconi anemia, complementation group W, MIM# 617784; Mode of inheritance: BIALLELIC, autosomal or pseudoautosomal | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mendeliome v0.0 | RFWD3 |
Zornitza Stark gene: RFWD3 was added gene: RFWD3 was added to Mendeliome_VCGS. Sources: Expert Review Green,Victorian Clinical Genetics Services Mode of inheritance for gene: RFWD3 was set to Unknown |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||